Recent Advances in Lipid Nanoparticles for Delivery of mRNA

Abstract

Messenger RNA (mRNA), which is composed of ribonucleotides that carry genetic information and direct protein synthesis, is transcribed from a strand of DNA as a template. On this basis, mRNA technology can take advantage of the body’s own translation system to express proteins with multiple functions for the treatment of various diseases. Due to the advancement of mRNA synthesis and purification, modification and sequence optimization technologies, and the emerging lipid nanomaterials and other delivery systems, mRNA therapeutic regimens are becoming clinically feasible and exhibit significant reliability in mRNA stability, translation efficiency, and controlled immunogenicity. Lipid nanoparticles (LNPs), currently the leading non-viral delivery vehicles, have made many exciting advances in clinical translation as part of the COVID-19 vaccines and therefore have the potential to accelerate the clinical translation of gene drugs. Additionally, due to their small size, biocompatibility, and biodegradability, LNPs can effectively deliver nucleic acids into cells, which is particularly important for the current mRNA regimens. Therefore, the cutting-edge LNP@mRNA regimens hold great promise for cancer vaccines, infectious disease prevention, protein replacement therapy, gene editing, and rare disease treatment. To shed more lights on LNP@mRNA, this paper mainly discusses the rational of choosing LNPs as the non-viral vectors to deliver mRNA, the general rules for mRNA optimization and LNP preparation, and the various parameters affecting the delivery efficiency of LNP@mRNA, and finally summarizes the current research status as well as the current challenges. The latest research progress of LNPs in the treatment of other diseases such as oncological, cardiovascular, and infectious diseases is also given. Finally, the future applications and perspectives for LNP@mRNA are generally introduced.

References 196

1. 1.

   Wirth T., Parker N., Ylä-Herttuala S. History of gene therapy. Gene. 2013;525:162-169.

   Not in our library10.1016/j.gene.2013.03.137

2. 2.

   Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., et al. T lymphocyte-directed gene therapy for ADA- SCID: Initial trial results after 4 years. Science. 1995;270:475-480.

   Not in our library10.1126/science.270.5235.475

3. 3.

   Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403-416.

   Not in our library10.1056/nejmoa2035389

4. 4.

   Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603-2615.

   Not in our library10.1056/nejmoa2034577

5. 5.

   He Q., Gao H., Tan D., Zhang H., Wang J.Z. mRNA cancer vaccines: Advances, trends and challenges. Acta Pharm. Sin. B. 2022;12:2969-2989.

   Not in our library10.1016/j.apsb.2022.03.011

6. 6.

   Au W.Y., Cheung P.P.-H. Effectiveness of heterologous and homologous COVID-19 vaccine regimens: Living systematic review with network meta-analysis. BMJ. 2022;377:e069989.

   Not in our library10.1136/bmj-2022-069989

7. 7.

   Zhang Z., Mateus J., Coelho C.H., Dan J.M., Moderbacher C.R., Gálvez R.I., Cortes F.H., Grifoni A., Tarke A., Chang J., et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185:2434-2451.e17.

   Not in our library10.1016/j.cell.2022.05.022

8. 8.

   Maruggi G., Zhang C., Li J., Ulmer J.B., Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol. Ther. 2019;27:757-772.

   Not in our library10.1016/j.ymthe.2019.01.020

9. 9.

   Dunbar C.E., High K.A., Joung J.K., Kohn D.B., Ozawa K., Sadelain M. Gene therapy comes of age. Science. 2018;359:eaan4672.

   Not in our library10.1126/science.aan4672

10. 10.

    Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816-821.

    Not in our library10.1126/science.1225829

11. 11.

    Posey A.D., Schwab R.D., Boesteanu A.C., Steentoft C., Mandel U., Engels B., Stone J.D., Madsen T.D., Schreiber K., Haines K.M., et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016;44:1444-1454.

    Not in our library10.1016/j.immuni.2016.05.014

12. 12.

    Hekele A., Bertholet S., Archer J., Gibson D.G., Palladino G., Brito L.A., Otten G.R., Brazzoli M., Buccato S., Bonci A., et al. Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect. 2013;2:e52.

    Not in our library10.1038/emi.2013.54

13. 13.

    Cobb M. Who discovered messenger RNA? Curr. Biol. 2015;25:R526-R532.

    Not in our library10.1016/j.cub.2015.05.032

14. 14.

    Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle In Vivo. Science. 1990;247:1465-1468.

    Not in our library10.1126/science.1690918

15. 15.

    Phua K.K., Leong K.W., Nair S.K. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J. Control. Release. 2013;166:227-233.

    Not in our library10.1016/j.jconrel.2012.12.029

16. 16.

    Dirisala A., Uchida S., Tockary T.A., Yoshinaga N., Li J., Osawa S., Gorantla L., Fukushima S., Osada K., Kataoka K. Precise tuning of disulphide crosslinking in mRNA polyplex micelles for optimising extracellular and intracellular nuclease tolerability. J. Drug Target. 2019;27:670-680.

    Not in our library10.1080/1061186x.2018.1550646

17. 17.

    Yen A., Cheng Y., Sylvestre M., Gustafson H.H., Puri S., Pun S.H. Serum Nuclease Susceptibility of mRNA Cargo in Condensed Polyplexes. Mol. Pharm. 2018;15:2268-2276.

    Not in our library10.1021/acs.molpharmaceut.8b00134

18. 18.

    Pardi N., Hogan M.J., Weissman D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 2020;65:14-20.

    Not in our library10.1016/j.coi.2020.01.008

19. 19.

    Karikó K., Buckstein M., Ni H., Weissman D. Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165-175.

    Not in our library10.1016/j.immuni.2005.06.008

20. 20.
    Opportunities and Challenges in the Delivery of mRNA-Based Vaccines · 2020

    No notice
21. 21.

    Dirisala A., Uchida S., Li J., Van Guyse J.F.R., Hayashi K., Vummaleti S.V.C., Kaur S., Mochida Y., Fukushima S., Kataoka K. Effective mRNA Protection by Poly(l-ornithine) Synergizes with Endosomal Escape Functionality of a Charge-Conversion Polymer toward Maximizing mRNA Introduction Efficiency. Macromol. Rapid Commun. 2022;43:e2100754.

    Not in our library10.1002/marc.202100754

22. 22.

    Patel S., Ashwanikumar N., Robinson E., DuRoss A., Sun C., Murphy-Benenato K.E., Mihai C., Almarsson Ö., Sahay G. Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA. Nano Lett. 2017;17:5711-5718.

    Not in our library10.1021/acs.nanolett.7b02664

23. 23.

    Ginn S.L., Amaya A.K., Alexander I.E., Edelstein M., Abedi M.R. Gene therapy clinical trials worldwide to 2017: An update. J. Gene Med. 2018;20:e3015.

    Not in our library10.1002/jgm.3015

24. 24.

    Yin H., Kanasty R.L., Eltoukhy A.A., Vegas A.J., Dorkin J.R., Anderson D.G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014;15:541-555.

    Not in our library10.1038/nrg3763

25. 25.

    Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1999;401:517-518.

    Not in our library10.1038/43977

26. 26.

    Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-419.

    Not in our library10.1126/science.1088547

27. 27.

    Ling S., Yang S., Hu X., Yin D., Dai Y., Qian X., Wang D., Pan X., Hong J., Sun X., et al. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. Nat. Biomed. Eng. 2021;5:144-156.

    Not in our library10.1038/s41551-020-00656-y

28. 28.

    Yin D., Ling S., Wang D., Dai Y., Jiang H., Zhou X., Paludan S.R., Hong J., Cai Y. Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat. Biotechnol. 2021;39:567-577.

    Not in our library10.1038/s41587-020-00781-8

29. 29.

    Petsch B., Schnee M., Vogel A.B., Lange E., Hoffmann B., Voss D., Schlake T., Thess A., Kallen K.J., Stitz L., et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 2012;30:1210-1216.

    Not in our library10.1038/nbt.2436

30. 30.

    Jarzebska N.T., Mellett M., Frei J., Kündig T.M., Pascolo S. Protamine-Based Strategies for RNA Transfection. Pharmaceutics. 2021;13:1210-1216.

    Not in our library10.3390/pharmaceutics13060877

31. 31.

    Dhaliwal H.K., Fan Y., Kim J., Amiji M.M. Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes. Mol. Pharm. 2020;17:1996-2005.

    Not in our library10.1021/acs.molpharmaceut.0c00170

32. 32.

    Hoerr I., Obst R., Rammensee H.G., Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 2000;30:1-7.

    Not in our library10.1002/1521-4141(200001)30:1<1::aid-immu1>3.0.co;2-#

33. 33.

    Chen R., Zhang H., Yan J., Bryers J.D. Scaffold-mediated delivery for non-viral mRNA vaccines. Gene Ther. 2018;25:556-567.

    Not in our library10.1038/s41434-018-0040-9

34. 34.

    Fotin-Mleczek M., Duchardt K.M., Lorenz C., Pfeiffer R., Ojkić-Zrna S., Probst J., Kallen K.J. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 2011;34:1-15.

    Not in our library10.1097/cji.0b013e3181f7dbe8

35. 35.

    Li L., Wei Y., Gong C. Polymeric Nanocarriers for Non-Viral Gene Delivery. J. Biomed. Nanotechnol. 2015;11:739-770.

    Not in our library10.1166/jbn.2015.2069

36. 36.

    Jere D., Jiang H.L., Arote R., Kim Y.K., Choi Y.J., Cho M.H., Akaike T., Cho C.S. Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin. Drug Deliv. 2009;6:827-834.

    Not in our library10.1517/17425240903029183

37. 37.

    Armbruster N., Jasny E., Petsch B. Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies. Vaccines. 2019;7:132.

    Not in our library10.3390/vaccines7040132

38. 38.

    Crommelin D.J.A., van Hoogevest P., Storm G. The role of liposomes in clinical nanomedicine development. What now? Now what? J. Control. Release. 2020;318:256-263.

    Not in our library10.1016/j.jconrel.2019.12.023

39. 39.

    Akinc A., Maier M.A., Manoharan M., Fitzgerald K., Jayaraman M., Barros S., Ansell S., Du X., Hope M.J., Madden T.D., et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 2019;14:1084-1087.

    Not in our library10.1038/s41565-019-0591-y

40. 40.

    Leroux J.C. Editorial: Drug Delivery: Too Much Complexity, Not Enough Reproducibility? Angew. Chem. Int. Ed. Engl. 2017;56:15170-15171.

    Not in our library10.1002/anie.201709002

Cited by papers we hold 1

• AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery · 2024
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.